Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69.6M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
56.6M
-
Shares change
-
+4.33M
-
Total reported value, excl. options
-
$583M
-
Value change
-
+$44.3M
-
Put/Call ratio
-
0.08
-
Number of buys
-
63
-
Number of sells
-
-35
-
Price
-
$10.30
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q2 2024
133 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q2 2024.
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.6M shares
of 69.6M outstanding shares and own 81.26% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (10.1M shares), Medicxi Ventures Management (Jersey) Ltd (7.46M shares), Carlyle Group Inc. (3.5M shares), Invesco Ltd. (3.14M shares), BlackRock Inc. (2.93M shares), JENNISON ASSOCIATES LLC (2.76M shares), Ensign Peak Advisors, Inc (2.24M shares), VANGUARD GROUP INC (2.21M shares), NEA Management Company, LLC (1.96M shares), and Avidity Partners Management LP (1.62M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.